A federal district judge imposed a lifetime ban against Martin Shkreli participating in the pharmaceutical industry and ordered him to pay $64.6 million to offset ill-gotten gains, stemming from his company's purchase of and huge price hike on the drug Daraprim.

“Pharma Bro” Who Drew Ire of 340B Providers and Drug Industry Alike Barred from Pharmaceutical Industry for Life

A federal district judge on Friday held “pharma bro” Martin Shkreli liable for antitrust claims brought by the Federal Trade Commission (FTC) and seven states.

U.S. Senior District Judge Denise Cote of the Southern District of New York imposed a lifetime ban against Shkreli participating in the pharmaceutical industry and ordered him to pay $64.6 million to offset ill-gotten gains. Shkreli’s former company and former business partner agreed last month to settle anticompetitive conduct claims against them.

A federal district judge on Friday held “pharma bro” Martin Shkreli liable for antitrust claims brought by the Federal Trade Commission (FTC) and seven states.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer